Products for Research Use Only

VHL Antibody

CAT: 0223-16-528Size: 100 µLDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0223-16-528Size:100 µL
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Background
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
NCBI Gene ID
7428
Swiss Prot
P40337
Host
Rabbit
Reactivity
Human, Mouse, Rat
Immunogen
A synthetic peptide corresponding to a sequence within amino acids 1-100 of human VHL (NP_937799.1) .
Clonality
Polyclonal
Conjugation
Unconjugated
Type
Primary Antibodies
Field of Research
Apoptosis, Cancer, Cell Cycle, Immunology
Purification
Affinity purification
Concentration
Batch dependent
Buffer
PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Store at -20˚ C. Avoid freeze / thaw cycles.
Calculated Molecular Weight
Observed: 24kDa
Fragment
IgG
Symbol
VHL
NCBI Official Name
Von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase
NCBI Organism
Homo sapiens
Other Product Names
VHL, von Hippel-Lindau tumor suppressor, HRCA1, RCA1, VHL1, elongin binding protein, von Hippel-Lindau syndrome, pVHL
Tested Applications
WB, IHC
Physical Properties
Liquid